Analyst firms · BofA Securities · APLS
BofA Securities APLS price target and rating history
Apellis Pharmaceuticals Inc. (APLS) · Health Care
BofA Securities rates Apellis Pharmaceuticals Inc. (APLS) Buy with a $28 price target, as of its latest action on Jan 21, 2026. It has published 3 rating actions on APLS since August 2023, including 1 upgrade and 2 downgrades. Across 3 firms with a APLS price target in the last 12 months, the median target is $28. BofA Securities's target matches it.
- Current rating
- Buy
- Price target
- $28
- Median target, all firms
- $28
- Actions on APLS
- 3
BofA Securities price target on APLS
Every BofA Securities rating on APLS
- Jan 21, 2026
- May 9, 2025
- Aug 1, 2023
How other firms rate APLS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $31 | Mar 13, 2026 |
| Barclays | Equal Weight | $24 | Jan 28, 2026 |
| BofA Securities | Buy | $28 | Jan 21, 2026 |
Questions about BofA Securities and APLS
- What is BofA Securities's price target for APLS?
- BofA Securities's latest stated price target for Apellis Pharmaceuticals Inc. (APLS) is $28, from its action on Jan 21, 2026.
- What is BofA Securities's rating on APLS?
- BofA Securities rates APLS Buy, a bullish rating, as of Jan 21, 2026.
- When did BofA Securities last change its view on APLS?
- On Jan 21, 2026, BofA Securities upgrades to Buy from Neutral, price target $28.
- How does BofA Securities's APLS target compare with other analysts?
- Across 3 firms with a APLS price target in the last 12 months, the median target is $28. BofA Securities's target matches it.
More APLS rating histories
All BofA Securities ratingsAPLS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.